Shard Capital’s Post

🚀 Major Milestone for Cizzle Biotechnology! 🧬 We’re thrilled to announce the signing of an exclusive licensing & partnership agreement for our cutting-edge CIZ1B biomarker test, designed to detect early-stage lung cancer across the USA & Canada. This is the critical first step in the Company's global licensing and partnership strategy to bring Cizzle's non-invasive, cost effective CIZ1B biomarker lung cancer blood test to market next year. ✨ Highlights: 💰 Initial Royalty Secured: We've received a $300,000 upfront payment, part of a 10% royalty on sales, with $2M guaranteed over the next 30 months. 🧑⚕️ Exclusive Rights to BIO: Our partner, BIO, will spearhead the marketing of the CIZ1B biomarker in North America, covering all costs related to clinical evaluations, accreditation, and marketing. 🏥 Collaboration with Moffitt Cancer Center: We're teaming up with one of the top US cancer centers to carry out real-world clinical trials. 📅 Launch Timeline: Full market launch targeted for April 2025, following CLIA accreditation by the end of 2024, with reimbursement codes secured. 📈 Equity Opportunity: Cizzle will also receive equity in BIO, sharing in future growth and success. 🌍 Global Vision: Retaining rights to further enhancements, positioning us for global expansion and development of a point-of-care (POC) test. This partnership marks a pivotal moment in our journey to transform lung cancer detection, aligning strategic goals to deliver life-saving innovations across North America and beyond. 💡 🔗 Read more: https://lnkd.in/ettK72cX #CizzleBiotechnology #LungCancerDetection #HealthcareInnovation #BiotechPartnership #CIZ1B #MedicalBreakthrough #CancerDetection #LifeSciences #GrowthOpportunity #USLaunch #GlobalExpansion

We are pleased to announce that Turner Pope Investments (TPI) Ltd acted as sole broker and placing agent for Aptamer Group plc, raising £2.83m through the issue of 1,415m new ordinary shares at 0.2p each. The deal is, in the main, dependent on approval at a 13th August general meeting. The fundraise follows Aptamer’s recent success with high-margin Fee-For-Service (‘FFS’) contracts with major pharma and consumer goods companies, boosting its order book to approximately £1.8m and  advanced pipeline of opportunities to around £2.1m.   With major partners like Unilever, AstraZeneca, NeuroBio, and other top-tier pharmaceutical groups progressing products utilising Aptamer’s binders, we believe that there is potential for significant financial and reputational growth for the Company. Today’s fundraising (plus existing cash) is projected to cover the Group’s working capital requirements through FY 2025/26, supporting both FFS operations and the development of advanced-stage licensing opportunities. Link to RNS: https://lnkd.in/dM3gX3kS RISK WARNING: Small companies can be highly volatile and are considered high risk speculative investments. You should only consider investing in small company shares if you have an appropriate degree of equity trading knowledge and experience. It may be difficult to sell the shares on a short-term basis without receiving a significantly lower price than you paid. This is the nature of illiquid investments and their large spread.

$QLGN Qualigen. Keep learning about low float stocks! 🚀📈 🏦 Market Cap: $3M. High-risk nanocap. 🧾 Float: 0.67M 📉 Short Interest: 14% (moderate levels not high) 📢 Key news (yesterday): Regained compliance with Nasdaq requirements. Understanding the dynamics of small floats and high short interest can bring exciting opportunities (and risks). Exploring the potential of these volatile gems! 💡 #LowFloat #Trading #Stocks https://lnkd.in/dwtJpYuu

🚀 Placing to raise £0.62 million and Appointment of Joint Broker 🚀 Cizzle Biotechnology has undertaken a conditional placing of 31,050,000 new ordinary shares of 0.01p each in the Company at a price of 2 pence per share raising approximately £0.62 million before expenses for the Company. Allenby Capital is acting as sole broker in connection with the Placing. The Placing has been conducted with existing and new investors. 📈 Placing Highlights: £0.62 million raised through the issuance of 31,050,000 new ordinary shares at 2p per share. Proceeds to fuel the completion of our first proposed commercial test to detect CIZ1B, further protect our Intellectual Property, and advance research with the University of York. Termination of the £500,000 loan facility agreement with E3 Fund SP, enhancing our financial flexibility. Allan Syms, Executive Chairman of Cizzle, expressed gratitude for the continued support and highlighted the potential of the net proceeds to drive manufacturing and scale-up initiatives vital for our growth. 🔍 Background & Reasons: Progress in developing our proprietary assay for the CIZ1B biomarker, crucial in early-stage lung cancer detection. Successful completion of an antibody development program with ProteoGenix, bolstering our proprietary rights. Net proceeds to be primarily deployed for scale-up and manufacturing, key milestones, IP protection, and regulatory advancements. 💼 Details of the Placing: Placing comprises 31,050,000 new Ordinary Shares at the Issue Price. Issue Price at a discount, reflecting investor confidence and support. Allenby Capital appointed as joint broker, amplifying our financial advisory prowess. 📈 Admission & Total Voting Rights: Application for New Shares to be admitted to trading on the Main Market of the London Stock Exchange. Expected commencement of dealings on or around 11 April 2024. Upon Admission, the Company will have 396,391,773 Ordinary Shares in issue, amplifying shareholder value. Exciting times lie ahead as we continue to innovate, drive growth, and deliver value to our stakeholders. Stay tuned for further updates on our journey towards revolutionising diagnostics. Read the full announcement here: https://lnkd.in/gE34ZN6H #CizzleBiotechnology #Diagnostics #Innovation #InvestmentOpportunity #Biotech #LSE #Placing #JointBroker #Admission

$AVU - 10 for 1 Split on the 21st of March can drive Adverum Biotechnologies to reversion: The company has price-to-book (P/B) ratio of 0.3. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adverum Biotechnologies had not issued any dividends in recent years. The entity had 10:1 split on the 28th of December 2023. https://lnkd.in/exnTpHZY #stocks #stocktwits #thematic_portfolio

IRB Approval for Phase I Clinical Trial Hemogenyx Pharmaceuticals plc (LSE: HEMO), a biopharmaceutical company developing innovative therapies and treatments for blood diseases, is pleased to announce that the Institutional Review Board (IRB) of the Company's first clinical site has granted approval to initiate a Phase I clinical trial of the Company's lead asset, HEMO-CAR-T, which has now been given the formal designation HG-CT-1, for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) in adults.   The proposed Phase 1 clinical trial is designed as a dose escalation study to assess the safety of HG-CT-1 in adult patients with R/R AML. Secondary clinical objectives are crucial for evaluating the broader impact of HG-CT-1 and include: ·      Estimating the efficacy of HG-CT-1 based on standard clinical response criteria for AML. ·      Estimating overall survival (OS) in evaluable subjects. ·      Estimating progression-free survival (PFS) in evaluable subjects. ·      Estimating duration of response (DoR) in evaluable subjects who achieve a clinical response.   These objectives are pivotal for assessing the overall clinical impact of HG-CT-1 on patients with R/R AML, a population with few remaining therapeutic options. This IRB approval represents a significant milestone for Hemogenyx Pharmaceuticals, enabling the Company to advance this promising therapy into clinical testing at one of the world's most prestigious cancer research institutions. https://lnkd.in/ewRsH4kz

RTW Biotech Opportunities Ltd this morning released its Annual Report and Financial Statements for the Year Ended 31 December 2023. Roderick Wong, MD Managing Partner and Chief Investment Officer of RTW Investments, LP, the Investment Manager commented: "We are delighted to report another strong year for the Group, with a NAV return of +23.5% for 2023, outperforming both the Russell 2000 Biotechnology Index and the Nasdaq Biotech Index, which returned +10.6% and +3.7%, respectively. The NAV per Ordinary Share has grown +82.3% since our IPO in 2019, from $1.04 to $1.90 as of 31 December 2023.   The Company's share price has not kept pace with the strong NAV performance, however, with continued NAV outperformance in comparison to the market and peers, and with the sector's fortunes having turned markedly in the fourth quarter of 2023, we expect the discount to narrow. There was a sharp reversal in the market performance in the final two months of 2023, as interest rate expectations inflected and a flurry of takeouts helped buoy sentiment in the biotech sector. The sector's vigorous move off the bottom is indicative of a re-evaluation after several years of fund flows out of the sector. With the fundamentals behind M&A remaining unchanged and a shrinking pool of high-quality assets to acquire, prospects for the sector's continued recovery look positive. Financing conditions in the sector may remain tighter than normal, however, and this environment enables RTW to flex the transactional capabilities it has built over the years to help support exciting companies and capture investment opportunities. With the acquisition of Arix Bioscience recently completed, the resultant increase in scale should prove well-timed to take advantage." The full announcement can be found below. Capital at risk. Professional investors only. For further information on RTW Biotech Opportunities Ltd (RTW), please contact Cadarn Capital at [email protected] Link to: https://lnkd.in/g_8ZywHt

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results #stockmarket #stocks #investing #businessnews #trading #daytrading #earnings #financialresults

Pfizer (PFE) is bouncing back with a 22% rise since late April, driven by advances in gene therapy for hemophilia A and an oral obesity drug. Despite a tough 2023, Pfizer's stock is up over 6% year-to-date and offers a 5.46% dividend yield. For Q1 2024, Pfizer reported $14.9 billion in revenues, down 19% from last year, but operational revenue grew 11%. Analysts forecast Q2 earnings of $0.45 per share and a target price of $33.68. Pfizer remains a “moderate buy” with strong future prospects and a consistent dividend history. #Pfizer #StockMarket #Pharmaceuticals #PFE #DividendStocks #EarningsReport #HealthcareStocks #InvestmentAnalysis #MarketUpdate #GeneTherapy #ObesityDrug #PfizerEarnings #StockPerformance #FinanceNews #KalkineTV #FinancialNews #StockMarketUpdate #InvestmentInsights #MarketAnalysis #EconomicTrends #StockTrading #FinancialEducation #MarketOutlook #InvestingTips #MarketWatch #GlobalEconomy #StockAnalysis #FinanceTalk #EconomicNews #StocksToWatch #MarketForecast #KalkineTVShow #FinancialTalkShow #InvestmentStrategies #MarketTrends

Tissue Regenix reports its unaudited interim results for the six months ended 30 June 2024 delivering continued progress across many areas of the business and marking the Group's eighth consecutive reporting period of growth. Highlights 📈 Group revenues increased by 16% to USD16.4 million 💵 Adjusted EBITDA* profit more than doubled to USD1.1 million 🌟 Profit before taxation of USD0.1 million & gross profit increased to 53% 💰 Cash position of USD3.5 million  ⬆️ A 29% year-on-year increase in tissue processing throughout H1 2024 🏢 Acquired the building in San Antonio that the Company has occupied since 2021 as part of the Phase 1 and 2 expansion plan Jonathan Glenn, Chair of Tissue Regenix Group plc, said: "It has been another impressive half for the Group and I am pleased to report continued success through the execution of the Group's 4S strategy. The management team has done a stellar job of driving the business forward through headwinds in certain segments and continues to identify expansion opportunities geographically as well as through new surgical indications. During H1 2024, there has been continued growth across all business segments and an improvement in profitability from H1 2023. We retain a strong cash position to see us through our current business plans, including the Phase 2 capacity expansion of the Group's facility in San Antonio, which is expected to complete in 2025." Read the full announcement HERE: https://lnkd.in/eSvYXnSB